Anti-Human C5 Therapeutic Antibody (Eculizumab)
Recombinant monoclonal antibody to Human C5. Eculizumab also is the first agent approved for the treatment of atypical hemolytic uremic syndrome (aHUS), an ultra-rare genetic disease that causes abnormal blood clots to form in small blood vessels throughout the body, leading to kidney failure, damage to other vital organs and premature death.
| Supplier | Creative Biolabs |
|---|---|
| Product # | TAB-008 |
| Pricing | Inquiry |
| Host | Mouse |
| Target | C5 |
| Species Reactivity | Human |
| Type | IgG2 / G4 - kappa |
| Applications | Suitable for use in ELISA, FC, IP, FuncS, IF, Neut, WB and most other immunological methods. |
| Storage | Store at -20°C for long-term storage. Store at 2-8°C for up to one month. Avoid freeze/thaw cycles. |